Soligenix (NASDAQ:SNGX)‘s stock had its “buy” rating reiterated by equities research analysts at Maxim Group in a report released on Thursday, AnalystRatings.com reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 441.93% from the company’s current price.
The analysts wrote, “Soligenix reported 1Q19 with a net loss of ($1.6M). The company received $1.1M in non-dilutive funding (grants and RiVax contracts) supporting pipeline programs. Soligenix ended the period with $7.2M in cash, although we anticipate the company should continue to receive non-dilutive funding that will extend the runway.””
NASDAQ SNGX traded down $0.02 on Thursday, hitting $0.74. The company’s stock had a trading volume of 85,815 shares, compared to its average volume of 91,281. Soligenix has a 52-week low of $0.65 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.46 and a current ratio of 2.20. The stock has a market cap of $12.57 million, a P/E ratio of -1.09 and a beta of 1.22.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SNGX. Renaissance Technologies LLC purchased a new position in shares of Soligenix in the 3rd quarter valued at approximately $188,000. Vanguard Group Inc. lifted its stake in shares of Soligenix by 46.5% in the 3rd quarter. Vanguard Group Inc. now owns 339,732 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 107,875 shares during the period. Finally, Vanguard Group Inc lifted its stake in shares of Soligenix by 46.5% in the 3rd quarter. Vanguard Group Inc now owns 339,732 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 107,875 shares during the period. Institutional investors own 9.88% of the company’s stock.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Featured Article: What strategies should day traders use to execute a trade?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.